Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Alnylam Pharmaceuticals, Inc. (ALNY) – Alnylam Pharmaceuticals, Inc. Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Alnylam Pharmaceuticals (ALNY) trades at $313.79, up 1.03% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong revenue growth, with 2025 revenue projected at $3.7 billion and a return to profitability with a net income margin of 8.44%. Recent earnings have mostly beaten expectations, and analyst sentiment is overwhelmingly positive with a 75% buy rating and a consensus price target of $451.60. Key developments include new clinical data presentations and strategic partnerships aimed at advancing its cardiovascular portfolio.
The outlook for ALNY is positive, driven by robust revenue growth, a profitable turnaround, and a promising pipeline. However, risks include high valuation multiples, competitive pressures in biotech, and reliance on successful drug development and regulatory approvals. Investors should weigh the strong analyst support against execution risks in a volatile sector.
Read full analysis

Key Stats

  • Market Cap
    $40.77B
  • Sector
    Health
  • 3M Drawdown
    -15.44%
  • Enterprise Value
    $39.14B
  • Dividend Yield
    -
  • Typical Hold Time
    39 days
$305.54
52W Low: $251.15
09 May 2025
52W High: $491.22
20 Oct 2025

Alnylam Pharmaceuticals, Inc. (ALNY) is currently valued at a market capitalization of $40.77B, with an enterprise value of $39.14B. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $251.15 and a high of $491.22, highlighting its annual price range. Over the past three months, Alnylam Pharmaceuticals, Inc. has recorded a drawdown of -15.44%, reflecting recent price volatility. On average, investors hold Alnylam Pharmaceuticals, Inc. for approximately 39 days, indicating typical investor behavior on the platform.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.


Technical Indicators
|
|
|
Overall Summary
Bearish (10)Neutral (11)Bullish (6)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $40.77B
  • Sector
    Health
  • 3M Drawdown
    -15.44%
  • Enterprise Value
    $39.14B
  • Dividend Yield
    -
  • Typical Hold Time
    39 days
$305.54
52W Low: $251.15
09 May 2025
52W High: $491.22
20 Oct 2025

Alnylam Pharmaceuticals, Inc. (ALNY) is currently valued at a market capitalization of $40.77B, with an enterprise value of $39.14B. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $251.15 and a high of $491.22, highlighting its annual price range. Over the past three months, Alnylam Pharmaceuticals, Inc. has recorded a drawdown of -15.44%, reflecting recent price volatility. On average, investors hold Alnylam Pharmaceuticals, Inc. for approximately 39 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!